胃轻瘫药物市场规模、份额、成长分析、按类型、药物类别、给药途径、应用、分销管道、地区、产业预测（2025-2032 年）

2023 年全球胃轻瘫药物市场规模为 57 亿美元，预计将从 2024 年的 60.1 亿美元成长到 2032 年的 92.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.5%。

胃轻瘫药物市场预计将稳定成长，主要原因是糖尿病盛行率上升（胃轻瘫的主要原因）以及人们对胃肠道疾病的认识不断提高。随着质子帮浦抑制剂和促动力製剂作为控制噁心、腹胀和排放延迟的有效解决方案的出现，对非侵入性、针对症状的治疗方法的需求不断增加。随着糖尿病相关併发症的增加，值得注意的是糖尿病胃轻瘫占大多数适应症。虽然零售药局仍然是主要的分销管道，但网路药局因其便利性正在获得发展。在竞争激烈的环境中，大型製药企业正在投资研发和策略联盟，以满足不断变化的患者需求。北美在强大的医疗保健系统和先进的治疗方法的支持下引领市场，而欧洲（尤其是德国和英国）在患者照护方面也取得了显着进展。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

胃轻瘫药物市场规模（按类型及复合年增长率）（2025-2032）

• 市场概览
• 品牌
• 非专利的

胃轻瘫药物市场规模（依药物类别和复合年增长率） (2025-2032)

• 市场概览
• 氨基水杨酸盐
• 消化酵素
• 质子帮浦抑制剂
• 泻药
• 止吐药
• H2拮抗剂
• 止泻
• 生技药品/生物相似药
• 其他的

胃轻瘫药物市场规模（依给药途径及复合年增长率）（2025-2032）

• 市场概览
• 口服
• 注射
• 其他的

胃轻瘫药物市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 克隆氏症
• 溃疡性大肠炎
• 逆流性食道炎
• IBS
• 其他的

胃轻瘫药物市场规模（依分销管道及复合年增长率）（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

胃轻瘫药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

    主要企业简介

    • 艾伯维公司（美国）
    • Evoke Pharma, Inc.（美国）
    • Vanda Pharmaceuticals Inc.（美国）
    • 武田药品工业株式会社（日本）
    • 阿斯特捷利康公司（英国）
    • 葛兰素史克公司（GSK）（英国）
    • Neurogastrx Inc.（美国）
    • Processa Pharmaceuticals, Inc.（美国）
    • 雅培实验室（美国）
    • Bausch Health Companies Inc.（加拿大）
    • Rhythm Pharmaceuticals, Inc.（美国）
    • CinDome Pharma（美国）
    • ANI Pharmaceuticals, Inc.（美国）
    • 强生公司（美国）
    • 辉瑞公司（美国）
    • 梯瓦製药工业股份有限公司（以色列）
    • 美敦力公司（爱尔兰）
    • 大冢製药株式会社（日本）
    • Theravance Biopharma, Inc.（美国）
    • 卡迪拉製药（印度）

结论和建议

Global Gastroparesis Drugs Market size was valued at USD 5.7 billion in 2023 and is poised to grow from USD 6.01 billion in 2024 to USD 9.23 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The gastroparesis drugs market is poised for steady growth, largely propelled by the rising prevalence of diabetes, a leading factor behind gastroparesis, coupled with heightened awareness of gastrointestinal disorders. The demand for non-invasive, symptom-focused therapies continues to rise, with proton pump inhibitors and prokinetic agents emerging as effective solutions for managing nausea, bloating, and delayed gastric emptying. Notably, diabetic gastroparesis dominates the indication segment amid increasing diabetes-related complications. Retail pharmacies remain the primary distribution channel, yet online pharmacies are gaining traction for their convenience. The competitive landscape features major pharmaceutical companies investing in R&D and strategic partnerships to address evolving patient needs. North America leads the market, supported by strong healthcare systems and advanced treatments, while Europe, particularly Germany and the UK, also showcases significant advancements in patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroparesis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastroparesis Drugs Market Segments Analysis

Global Gastroparesis Drugs Market is segmented by Type, Drug Class, Route of Administration, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generics. Based on Drug Class, the market is segmented into Amino salicylates, Digestive enzymes, Proton Pump Inhibitors, Laxatives, Anti-Emetics, H2 Antagonists, Anti-Diarrheal, Biologics/Biosimilar and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on Application, the market is segmented into Crohn's disease, Ulcerative colitis, GERD, IBS and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastroparesis Drugs Market

A significant factor propelling the Global Gastroparesis Drugs market is the increasing prevalence of diabetes, which has a strong association with the condition of gastroparesis. As the number of individuals diagnosed with Type 1 and Type 2 diabetes rises worldwide, the occurrence of related complications, such as diabetic gastroparesis, is becoming more pronounced, thus creating a heightened demand for effective medical treatments. A report from the International Diabetes Federation in January 2024 highlighted a surge in diabetes cases globally, particularly in regions like Asia and North America. This trend has prompted pharmaceutical companies, including Evoke Pharma, to enhance the production of medications like Gimoti, focusing specifically on addressing diabetic gastroparesis.

Restraints in the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market faces significant challenges due to the limitations of currently available treatments, which primarily provide symptomatic relief while often causing undesirable side effects that discourage long-term use and diminish overall patient satisfaction. Additionally, regulatory obstacles persist, as evidenced by the FDA's April 2024 decision to reject the approval of a new prokinetic agent from PharmaNova, citing insufficient long-term safety data. This situation highlights the complexities involved in developing new and effective therapies, underscoring the difficulties that pharmaceutical companies encounter in navigating the regulatory landscape to bring safe and innovative treatments to market.

Market Trends of the Global Gastroparesis Drugs Market

The Global Gastroparesis Drugs market is undergoing a significant transformation, driven by the integration of artificial intelligence in drug discovery and clinical trial design. As pharmaceuticals grapple with the complexities of tailoring treatments for this multifaceted disorder, AI technologies are revolutionizing R&D processes. Recent collaborations, such as Quris-AI's partnership with NeuroGasTx, exemplify this trend, demonstrating how AI can enhance patient simulations and optimize trial efficiency. Such innovations have led to a 25% increase in enrollment rates and reduced costs, thereby accelerating the development timeline for new therapies. This shift towards AI-driven methodologies is expected to enhance treatment efficacy and patient outcomes in the gastroparesis market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Gastroparesis Drugs Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Gastroparesis Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Amino salicylates
• Digestive enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-Emetics
• H2 Antagonists
• Anti-Diarrheal
• Biologics/Biosimilar
• Others

Global Gastroparesis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Others

Global Gastroparesis Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Crohn's disease
• Ulcerative colitis
• GERD
• IBS
• Others

Global Gastroparesis Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gastroparesis Drugs Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Route of Administration, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evoke Pharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurogastrx Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Processa Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CinDome Pharma (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ANI Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations